ServiziMenu principale

<< Torna a "Ricerca Studi"

AML1718 - Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia.

Studio Clinico

Patologia: Neoplasie ematologiche

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: II

Linee di trattamento: Non applicabile

Criteri di inclusione: 

- Patients with documented/confirmed new onset non-m3 acute myeloid leukemia, according to WHO 2017 will be eligible for this study.
- Hematological illness has to be graded intermediate or high risk according ELN criteria
- Patients ≥ 18 years old and ≤ 65 years old
- ECOG performance status ≤ 2.
- Patients with a life expectancy >12 weeks
- Patients may have AML which has arisen from prior therapies or other antecedent disorder
- Adequate hepatic function
- Adequate pancreatic function
- Adequate renal function assessed by: Serum creatinine within reference laboratory ranges or creatinine clearance (by Cockcroft Gault formula, see Appendix 2) ≥ 50 mL/min for patients in whom, in the Investigator's judgment, serum creatinine level may not adequately reflect renal function.
- All non-hematological adverse events must have resolved to NCI-CTCAE Grade ≤ 2 prior to starting therapy.
- Patients must be considered by Investigator suitable to receive combination chemotherapy.
- Combination chemotherapy has not to be considered toxic without expectation of any benefit for the patient
- For females of childbearing potential, a negative pregnancy test must be documented within 72 hours prior to the first study drug administration.
- All patients must be willing to use effective methods of contraception, during the treatment period and for 100 days after the last dose of Venetoclax. Female patients must be postmenopausal (≥ 1 year of amenorrhea), surgically sterile, or they must agree to use 2 adequate methods of contraception with at least one method with a failure rate of ≤ 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner) and the second preferably a physical barrier method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception. Male patients must be surgically sterile or agree to use an acceptable method of contraception.
- Patient must be willing to submit the blood sampling and bone marrow sampling for the PK and PD analyses and exploratory biomarkers.
- Ability to understand and willingness to sign an informed consent form.
- Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Criteri di esclusione: 

- Patients with low risk AML according ELN criteria
- Patients with current clinical evidence of CNS leukemia.
- Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy with the exception of Hydroxyurea (HU) or 6-Mercaptopurine (6MP) in patients who need to continue this agent to maintain WBC count ≤10,000/mm3. HU and 6MP must be discontinued at the time of initiation of study medications.
- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study including but not limited at:
- unstable angina
- Patients who are on anti-microbial agents with therapeutic intent.

Schema di trattamento: 

Cohort 1: FLAI + V400 mg
Cohort 2: FLAI + V600 mg

Trattamento sperimentale: 


Trattamento di controllo: 


Obiettivi primari dello studio: 

Number of patients achieving complete response (CR) after course 1 or course 2 if course 2 is administered (CR + CRi + CRp) [ Time Frame: At 24 months from study entry ]
Efficacy in new onset, non ELN Low risk AML (safety run-in, part1, and part2). Effectiveness of Venetoclax added in combination with chemotherapy in obtaining Complete remission in new onset, non ELN Low risk AML (safety run-in, part1, and part2).

Centri partecipanti

Nord Italia

Ospedale Papa Giovanni XXIII Bergamo
Piazza OMS 1 - 24127 Bergamo - BG

Riferimento: Prof. Alessandro Rambaldi


Ospedale S.Orsola Malpighi, Università di Bologna
Via Pietro Albertoni 15 - 40138 Bologna - BO
UOC Ematologia


ASST Spedali Civili di Brescia
Piazzale Spedali Civili 1 - 25123 Brescia - BS
UO Ematologia


IRCCS - IRST Meldola Dino Amadori
Via P. Maroncelli 40 - 47014 Meldola - FC


IRCCS A.O.U. San Martino - IST
Largo Rosanna Benzi 10 - 16132 Genova - GE
UO Clinica Ematologica


Grande Ospedale Metropolitano Niguarda
Piazza Ospedale Maggiore 3 - 20162 Milano - MI
SC Ematologia - NB: Arruolamento pazienti non ancora attivo


IRCCS Istituto Nazionale dei Tumori
Via Venezian 1 - 20133 Milano - MI
SC Ematologia


Ospedale San Raffaele di Milano
Via Olgettina 60 - 20132 Milano - MI
UO Ematologia e Trapianto di Midollo

Riferimento: Prof. Fabio Ciceri


Istituto Clinico Humanitas Rozzano
Via Manzoni 56 - 20089 Rozzano - MI
UO Oncologia Medica ed Ematologia


Azienda Ospedaliero-Universitaria di Parma
Via Gramsci 14 - 43126 Parma - PR
UOC Ematologia e CTMO - NB: Arruolamento pazienti non ancora attivo


IRCCS Policlinico San Matteo
Viale Golgi 19 - 27100 Pavia - PV
UO Ematologia


Centro di Riferimento Oncologico
Via Franco Gallini 2 - 33081 Aviano - PN


Ospedale S. Maria delle Croci, Ravenna
Viale Randi 5 - 48121 Ravenna - RA
Dipartimento Oncologico


AOU Città della Salute e della Scienza di Torino
Corso Bramante 88 - 10126 Torino - TO
Ospedale San Giovanni Battista Molinette - SC Ematologia


AOU Città della Salute e della Scienza di Torino
Corso Bramante 88 - 10126 Torino - TO
Ospedale San Giovanni Battista Molinette - Dipartimento di Oncologia ed Ematologia S.C.


Ospedale San Bortolo, Vicenza
Viale Rodolfi 37 - 36100 Vicenza - VI
UOC Ematologia


Centro Italia

AOU Careggi
Largo Brambilla 3 - 50134 Firenze - FI
Ematologia - NB: Arruolamento pazienti non ancora attivo


Università La Sapienza Policlinico Umberto I
Viale del Policlinico 155 - 00161 Roma - RM
Dip. Biotecnologie Cellulari ed Ematologia


Università La Sapienza Policlinico Umberto I
Viale del Policlinico 155 - 00161 Roma - RM
Dip. di Medicina Traslazionale e di Precisione - NB: Arruolamento pazienti non ancora attivo

Riferimento: Prof. Maurizio Martelli


Azienda Ospedaliera Universitaria Senese
Viale Bracci 16 - 53100 Siena - SI
UOC Ematologia e Trapianti


Sud Italia e isole

AOUP V. Emanuele Pres Osp Ferrarotto Alessi
Via Salvatore Citelli 6 - 95123 Catania - CT
NB: Arruolamento pazienti non ancora attivo


Ospedale Andrea Tortora
Via De Gasperi 1 - 84016 Pagani - SA


OORR S.Giovanni di Dio e Ruggi d'Aragona
Via San Leonardo 1 - 84131 Salerno - SA
Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche

Informazioni Generali


Numero di iscrizione a registro: 2018-000392-33

Data di inserimento: 20.09.2022


Gruppo Italiano Malattie EMatologiche dell'Adulto

Principal Investigator ITALIA

Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- IRCCS

Riferimento: Prof. Giovanni Martinelli

Telefono: 0543739100


Localita: Meldola (FC)


<< Torna a "Ricerca Studi"